Back to top

Analyst Blog

Dr. Reddy’s Laboratories (RDY - Analyst Report) recently announced the US launch of its generic version of AstraZeneca’s (AZN - Analyst Report) drug, Seroquel. Late last month, the US Food and Drug Administration (FDA) had approved Dr. Reddy’s abbreviated new drug application (ANDA) for the generic drug. Seroquel is approved for the treatment of schizophrenia and bipolar mania.

According to IMS Health, US sales of the Seroquel brand amounted to about $4.6 billion for the 12 months ended December 31, 2011.

Last month, Dr. Reddy’s launched its generic version of Pfizer Inc.’s (PFE - Analyst Report) antipsychotic drug, Geodon (ziprasidone) in the US. The drug is approved for the treatment of schizophrenia and bipolar disorder.

We expect generic launches at regular intervals to add to Dr. Reddy’s Global Generic revenues, which soared 57% year-over-year to $402 million in the third quarter of fiscal 2012.

During the reported quarter, generics’ revenues climbed 133% in North America, 15% in Russia and other CIS (Commonwealth of Independent States) markets, 14% in Europe and 11% in India. Growth was mainly driven by the launch of a generic version of Eli Lilly & Co.’s (LLY - Analyst Report) Zyprexa (olanzapine) 20 mg.

Our Take

We currently have a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #2 Rank (Buy rating) in the short-run. We believe Dr. Reddy’s is in a strong position to benefit from the huge potential presented by the US generics market, as quite a few blockbuster drugs such as Johnson & Johnson’s (JNJ - Analyst Report) Concerta and Pfizer’s  Lipitor have lost patent exclusivity and more drugs are slated to go off-patent in the coming years.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.20 +2.73%
THE PANTRY… PTRY 21.08 +2.38%
CLAYTON WIL… CWEI 117.60 +2.04%
INTEL CP INTC 35.14 +1.84%